Pangu
Contact
Clinical Trials
Patients

Skip to content

Company
Our Science
R&D
Patients
Careers
- Working at aTyr
- Career Opportunities
Investors and Media

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

Exposure-Response Analyses of Efzofitimod in Patients With Pulmonary Sarcoidosis

Frontiers in Pharmacology, 2023

« Therapeutic Doses of Efzofitimod Significantly Improve Multiple Pulmonary Sarcoidosis Efficacy Measures

Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models »

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

By continuing to browse this site, you agree to our use of cookies.

MENU

Company
Our Science
R&D
Patients
Careers
- Career Opportunities
- Working at aTyr
Investors and Media
Privacy Policy